Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

The efficacy and safety of combining bevacizumab (7.5 and 15 mg/kg) with docetaxel as first-line therapy for human epidermal growth factor receptor 2 (HER2) -negative, locally recurrent or metastatic breast cancer (MBC) was investigated in a three-arm, placebo-controlled, phase III trial. Patients (...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of clinical oncology Ročník 28; číslo 20; s. 3239
Hlavní autoři:	Miles, David W, Chan, Arlene, Dirix, Luc Y, Cortés, Javier, Pivot, Xavier, Tomczak, Piotr, Delozier, Thierry, Sohn, Joo Hyuk, Provencher, Louise, Puglisi, Fabio, Harbeck, Nadia, Steger, Guenther G, Schneeweiss, Andreas, Wardley, Andrew M, Chlistalla, Andreas, Romieu, Gilles
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 10.07.2010
Témata:	Adult Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - pathology Drug Administration Schedule Female Humans Middle Aged Neoplasm Metastasis Neoplasm Recurrence, Local - drug therapy Placebos - administration & dosage Receptor, Epidermal Growth Factor - metabolism Taxoids - administration & dosage
ISSN:	1527-7755, 1527-7755
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!